Trials / Not Yet Recruiting
Not Yet RecruitingNCT06562088
A Drug-Drug Interaction (DDI) Study of HDM1002 With Rifampicin and Itraconazole in Healthy Subjects
A Phase I, Open-Label, Parallel, Fixed-Sequence Study to Evaluate the Effect of Repeated Administration of Rifampicin or Itraconazole on the Pharmacokinetics of HDM1002 in Healthy Adult Chinese Subjects
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to characterize the effect of rifampicin and itraconazole on the PK of single dose of HDM1002 in healthy adult subjects. The safety and tolerability of HDM1002 and rifampicin or itraconazole when given separately or together will also be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HDM1002 and rifampicin | Administered orally |
| DRUG | HDM1002 and itraconazole | Administered orally |
Timeline
- Start date
- 2024-08-16
- Primary completion
- 2024-11-19
- Completion
- 2024-12-30
- First posted
- 2024-08-20
- Last updated
- 2024-08-20
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06562088. Inclusion in this directory is not an endorsement.